EUVIMEDEUVIMED entdecken
Crossref

Preclinical evaluation of the 18F-labeled xanthine 1-NBX as a potential PET tracer for cerebral A1 adenosine receptors

F Wedekind, A Matusch, S Humpert, S Stüsgen, M Holschbach, D Bier, D Schneider, A Braun, S Klein, A Oskamp, B Neumaier, A Drzezga und 1 weitere

Nuklearmedizin - NuclearMedicine · 01.04.2026 · 65 (02) · 128

DOI: 10.1055/s-0046-1818243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2026. Verfasst von F Wedekind und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ziel/Aim: Cerebral A 1 adenosine receptors (A 1 ARs) have been widely investigated in preclinical and clinical studies using positron emission tomography (PET). The first A 1 AR radioligand used in human PET studies was 8-cyclopentyl-3-(3-[ 18 F]fluoropropyl)-1-propyl-xanthine, [ 18 F]CPFPX. It is considered the gold standard for in vivo A 1 AR imaging; however, it is rapidly metabolized. Given that in vivo binding of xanthine-based A 1 AR radioligands is primarily determined by their binding affinity, the objective was to identify radioligands with higher affinity and optimized imaging quality. 8-(1-norbornyl)-3-(3-fluoropropyl)-1-propylxanthine (1-NBX), a norbornyl-substituted CPFPX analog, exhibited enhanced A 1 AR affinity and selectivity compared to CPFPX in vitro [ 1 ]. Therefore, we investigated the in vivo uptake, binding behavior, and metabolic stability of [ 18 F]1-NBX in PET studies in rats. Methodik/Methods: We performed dynamic, 3-hour PET scans with [ 18 F]1-NBX in male Sprague-Dawley rats, followed by ex vivo gamma counting of organs. We determined kinetics and proportion of unbound radioligand in arterial plasma samples. Blood plasma, brain tissue as well as urine, liver and lung were analyzed for metabolites by thin layer chromatography (radio-TLC). The radioligand was produced using different synthesis techniques (manual versus automated method) and compared with regard to the imaging quality in the PET scans. Ergebnisse/Results: [ 18 F]1-NBX showed high region-specific binding in the brain corresponding to the known A 1 AR expression pattern. Radioligand binding in the olfactory bulb was low, qualifying this region as reference for kinetic modelling. The proportion of parent [ 18 F]1-NBX in the blood after three hours of measurement was relatively high. Stable quantification was also possible after a shorter scan time. Up to seven metabolite species were detected in blood and organs, while in brain metabolites amounted to less than 5%. Schlussfolgerungen/Conclusion: Overall, [ 18 F]1-NBX appears to have favorable in vivo binding properties in the imaging of cerebral A 1 ARs. While binding potentials and signal to background ratio were comparable to those of [ 18 F]CPFPX, [ 18 F]1-NBX was metabolically more stable. Publication History Article published online: 02 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Wedekind, F., Matusch, A., Humpert, S., Stüsgen, S., Holschbach, M., Bier, D., Schneider, D., Braun, A., Klein, S., Oskamp, A., Neumaier, B., Drzezga, A., & Bauer, A. (2026). Preclinical evaluation of the 18F-labeled xanthine 1-NBX as a potential PET tracer for cerebral A1 adenosine receptors. Nuklearmedizin - NuclearMedicine, 65(02), 128. https://doi.org/10.1055/s-0046-1818243

Vancouver

Wedekind F, Matusch A, Humpert S, Stüsgen S, Holschbach M, Bier D, et al. Preclinical evaluation of the 18F-labeled xanthine 1-NBX as a potential PET tracer for cerebral A1 adenosine receptors. Nuklearmedizin - NuclearMedicine. 2026;65(02):128. doi:10.1055/s-0046-1818243

BibTeX
@article{Wedekind2026,
  author = {Wedekind, F and Matusch, A and Humpert, S and Stüsgen, S and Holschbach, M and Bier, D and Schneider, D and Braun, A and Klein, S and Oskamp, A and Neumaier, B and Drzezga, A and Bauer, A},
  title = {Preclinical evaluation of the 18F-labeled xanthine 1-NBX as a potential PET tracer for cerebral A1 adenosine receptors},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  volume = {65},
  number = {02},
  pages = {128},
  doi = {10.1055/s-0046-1818243}
}
Kostenlos starten →